Proyecto CDTI: Investigación de una nueva vacuna para una enfermedad respiratoria humana

Hipra Scientific S.L.U, Polypeptide Therapeutic Solutions S.L., Biotechvana S.L. y Nostrum Biodiscovery constituyen el consorcio de empresas que participan en el proyecto “Investigación de una nueva vacuna para una enfermedad respiratoria humana”, subvencionado por el CDTI (Centro para el Desarrollo Tecnológico Industrial), apoyado por el Ministerio de Ciencia e Innovación y financiado por la Unión Europea – NextGenerationEU. El objetivo general del proyecto consiste en el diseño de una vacuna que sea segura, inmunogénica y eficaz frente al virus respiratorio sincitial.

Hipra Scientific S.L.U, Polypeptide Therapeutic Solutions S.L., Biotechvana S.L. i Nostrum Biodiscovery constiutuixen el consorci d’empreses que participen en el projecte “Investigació d’una nova vacuna per una malaltia respiratòria humana”, subvencionat pel CDTI (Centre pel Desenvolupament Tecnològic Industrial), recolzat pel Ministeri de Ciència i Innovació i finançat per la Unió Europea – NextGenerationEU. L’objectiu general del projecte consisteix en el disseny d’una vacuna segura, immunogènica i eficaç contra el virus respiratori sincitial.

Hipra Scientific S.L.U, Polypeptide Therapeutic Solutions S.L., Biotechvana S.L. and Nostrum Biodiscovery constitute the consortium of enterprises participating in the project “Research of a new vaccine for a human respiratory disease”,  granted by the CDTI (Center for Industrial Technological Development), and supported by the Ministry of Science and Innovation and financed by the European Union – NextGenerationEU. The main objective of this project is to design a safe immunogenic and effective vaccine against the respiratory syncytial virus.

The Latest from Curapath
Curapath receives representatives of the Valencian Generalitat in their facilities at the Valencia technology park

Paterna, May 9, 2025 – Curapath, a global life sciences company specializing in the custom design, development, and manufacturing of advanced drug delivery systems, yesterday welcomed...

Club Of The Valencian Community
Curapath joins The Innovation Club of the Valencian Community and participates in its General Assembly

February 24, 2025, Valencia, Spain – In a significant step towards strengthening its presence in the biotechnology and pharmaceutical sector, CURAPATH has been officially accepted...

Curapath, working towards equity and inclusive development, is pleased to announce the approvement and publishment of its Gender Equality Plan (GEP)

November 21, 2024, Valencia, Spain, At Curapath, we believe that a fair, inclusive, and diverse workplace is the foundation for innovation and collective well-being. In alignment...